查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2099606

乳癌液態生物檢體設備市場－2026-2032年全球市場預測

Breast Cancer Liquid Biopsy Testing Devices Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，乳癌液態生物檢體設備市場規模將達到 24.4 億美元，複合年成長率為 8.41%。

主要市場統計數據
基準年 2025 13.8億美元
預計年份：2026年 14.9億美元
預測年份 2032 24.4億美元
複合年成長率 (%) 8.41%

乳癌液態生物檢體儀器在精準腫瘤學中日益重要，它們能夠以微創方式檢測和監測血液及其他體液中腫瘤來源的生物標記。這些儀器支持對循環腫瘤DNA、循環性腫瘤細胞、細胞外囊泡、 微型RNA、甲基化特徵、片段組體學模式和蛋白質標記的分析，幫助臨床醫生在腫瘤獲取受限、疾病異質性或需要臨床重複取樣時，補充組織切片檢查。在乳癌治療中，液態生物檢體尤其適用於識別具有治療意義的基因組突變、監測治療反應、檢測抗藥性以及輔助進行性或轉移性疾病的治療選擇。次世代定序、數位PCR、微流體技術、自動化樣品製備、高靈敏度濃縮技術和生物資訊平台的快速發展推動了該領域的進步，提高了分析靈敏度和工作流程的可重複性。雖然人們越來越需要證據證明液態生物檢體能夠改善醫療保健系統的決策、患者預後和資源利用，而不是取代臨床上必要的組織病理學檢查，但監管期望、臨床有效性要求、數據完整性標準和保險報銷機制仍然是採用這項技術的主要挑戰。

乳癌液態生物檢體領域的變革性變化

乳癌液態生物檢體領域正從探索性生物標記研究轉向臨床整合的診斷工作流程。其中一項關鍵轉變是從單一標記檢測轉向更廣泛的多分析物、多基因方法，這種方法能夠捕捉轉移部位的腫瘤異質性，並追蹤抗藥性機制，例如內分泌治療逃脫和標靶治療抗藥性。實驗室設備也不斷發展，從高度人工操作的集中式檢查室系統轉向更自動化、標準化和分散式的平台，從而縮短週轉時間並降低檢體處理的變異性。臨床應用範圍已從突變檢測擴展到可測量殘留病灶的檢測、治療抗藥性監測、分子水平復發監測和即時疾病監測，但這些應用的實施需要強力的證據支持並與臨床指南保持一致。另一個重大變化是更重視檢測前的品管，包括採血管的性能、血漿分離方案、核酸儲存、溶血評估、白血球污染管理以及監管鏈程序。這些因素直接影響檢測的可靠性。與電子健康記錄、分子腫瘤學委員會、實驗室資訊系統和臨床決策支援系統的互通性，進一步將液態生物檢體從獨立測試轉變為整合的精準醫療工具。

人工智慧對液態生物檢體檢測的累積影響

人工智慧 (AI) 透過改進訊號檢測、突變解讀、檢測最佳化和工作流程自動化，加速了乳癌液態生物檢體檢測設備的開發和臨床效用。 AI 驅動的生物資訊學有助於區分低頻腫瘤來源突變與定序雜訊、克隆性造血、種系背景和技術偽影。這對於復發監測和低腫瘤負荷疾病評估等高靈敏度應用至關重要。機器學習模型也被用於整合基因組、片段組、表觀基因組、蛋白質表觀基因、影像、病理、治療史和臨床數據，以支持更全面的癌症分析。在設備開發中，AI 可以最佳化微流體捕獲、基於影像的循環性腫瘤細胞檢測、與數位病理的匹配、檢查室品管和通量管理。然而，AI 的累積效應取決於透明的檢驗、具有代表性的訓練資料集、偏差減少、可解釋性、網路安全、可審計性以及符合監管標準的文件。對於臨床應用而言，人工智慧驅動的液態生物檢體系統必須保持臨床醫生的信任，遵守資料保護標準，並證明其在目標人口、檢體類型、設備、定序試劑和檢查室環境中具有可重複性。

亞太地區、歐洲、北美、拉丁美洲、非洲和中東的關鍵區域洞察

亞太地區是乳癌液態生物檢體設備的重點市場，這主要得益於中國、印度、日本、韓國和澳洲等國家癌症篩檢活動的活性化、腫瘤基礎設施的擴建以及分子診斷技術的廣泛應用。該地區對擴充性的檢測流程的需求日益成長，這些流程能夠適應從先進的都市區癌症中心到資源匱乏的醫療機構等各種不同的醫療環境。公共衛生部門也持續將早期癌症檢測和改善病理服務的可及性作為優先事項。歐洲以以指引為基礎的癌症診療、跨境研究合作、國家癌症控制計畫以及監管機構對診斷品質、資料保護、臨床證據和體外診斷效能的重視，展現出強勁的發展勢頭。北美憑藉其成熟的精準癌症診療網路、完善的分子病理學能力、活躍的臨床試驗生態系統、系統的法律規範以及基因組分析在先進癌症治療中的廣泛應用，仍然是臨床應用領域的領先地區。在拉丁美洲，透過私人癌症網路、大學附屬癌症中心和旨在改善先進診斷可及性的當地舉措，液體活體組織切片的應用正在逐步推進，但成本效益、自付費用、報銷方案的差異以及實驗室基礎設施的不平衡仍然是重要的障礙。在非洲，液體活體組織切片的應用並不均衡，集中式參考檢查室、國際研究夥伴關係以及擴大癌症診斷可及性的努力帶來了機遇，但基礎設施匱乏、人員短缺、晚期癌症診斷困難以及對成本的敏感性等因素仍然制約著液體活體組織切片的應用。在中東，對腫瘤學現代化、基因組醫學計畫、三級醫療基礎設施和國家醫療改革舉措的投資，正在支持在具備專業腫瘤服務和分子檢查室的地區選擇性地採用液態生物檢體來管理進行性乳癌。

北約、七國集團、金磚國家、歐盟、東協和海灣合作理事會的關鍵集團分析

許多北約成員國擁有先進的醫療保健系統，對互通性、安全可靠且具彈性的診斷技術有著迫切的需求。在那些將精準腫瘤學納入國家癌症控制策略，並將網路安全、醫療連續性和受保護健康資料交換視為重中之重的國家，這種需求尤其突出。在七國集團（G7）國家，人們普遍支持透過已建立的臨床研究網路、專業的癌症治療中心、成熟的分子病理學基礎設施以及關於高級保險報銷的討論，快速部署乳癌液態生物檢體設備，儘管臨床效用、分析有效性和成本效益的證據標準仍然十分嚴格。金磚國家擁有豐富的資源，具備多元化的機遇，包括大規模的患者群體、不斷完善的腫瘤學基礎設施、日益​​成長的分子診斷國家興趣以及對癌症治療可及性的政策關注，但其部署仍受到價格壓力、監管差異、當地生產優先事項以及都市區醫療資源獲取差距等因素的影響。歐盟透過統一的體外診斷醫療設備法規、健全的公共衛生體系、跨境研究計畫以及對循證診斷的重視，為體外診斷技術的應用提供了系統的環境；然而，其具體實施情況會因報銷政策、國家分子檢測能力和區域檢查室網路的不同而有所差異。在東南亞國協，隨著醫療體係不斷擴展癌症診斷、提升區域檢測能力和提供專業的癌症護理服務，體外診斷技術的重要性日益凸顯，尤其是在市場規模龐大且私營專業醫療體系發達的地區，其應用更為顯著。在海灣合作理事會國家，政府主導的醫療改革、基因組醫學舉措的拓展、對數位醫療的投資以及先進腫瘤學服務的開發，都催生了對符合國際臨床標準和認證檢查室規範的高品質液態生物檢體工作流程的需求。

各國乳癌液態生物檢體設備的關鍵訊息

在中國，癌症基因組學、醫院分子診斷、臨床腫瘤學研究以及國產醫療設備的快速發展，推動了人們對乳癌液態生物檢體技術的廣泛關注。美國憑藉其先進的腫瘤診療路徑、廣泛的臨床試驗活動、成熟的轉移性疾病分子譜分析以及與監管機構在複雜診斷方面積極的合作，成為乳癌液態生物檢體設備的領先應用國。日本先進的醫療基礎設施、精準醫療政策、高標準的診斷品質以及分子檢測與專科腫瘤診療的緊密結合，也促進了該技術在日本的應用。印度由於疾病負擔沉重、私人醫療保健體係不斷擴展、分子檢測網路日益完善以及對適用於不同醫療環境的具成本效益檢測的需求，具有巨大的長期發展潛力。德國在診斷檢查室、腫瘤學研究能力和嚴格的管理體制方面擁有豐富的經驗。同時，英國透過其國家癌症戰略和集中式基因組服務支持分子檢測，建構了一套系統化的路徑，最終實現臨床檢驗的液態生物檢體的應用。澳洲受益於其完善的癌症登記系統、學術研究、分子病理學的專業知識，以及國家致力於確保其地理分散的人口都能公平地獲得醫療服務的承諾。另一方面，法國則強調透過癌症網路和臨床計畫整合檢驗的精準醫療。韓國結合了先進的數位醫療基礎設施、強大的生物技術能力以及對精準腫瘤學的高度臨床興趣，從而推動了三級醫療機構和研究型癌症中心對精準腫瘤學的應用。義大利和西班牙正透過專科醫院和研究網路來推進分子腫瘤學的應用，但保險報銷和醫療保健系統的區域差異正在影響其應用。加拿大強調透過省級醫療保健系統和癌症機構進行循證整合，但醫療服務的可近性取決於保險報銷和檢查室能力。在俄羅斯，腫瘤學現代化的努力正在不斷推進，但醫療服務的可近性、區域醫療保健差異以及國際技術的可用性各不相同。巴西在腫瘤專科基礎設施方面領先許多拉丁美洲國家，液態生物檢體的應用主要集中在主要都市區。同時，在墨西哥，受此類方法需求的推動，私立癌症治療機構和參考實驗室擴大使用微創診斷方法，但受到成本差異的限制。

為行業領導者提供的實用建議

產業領導者應檢驗經臨床驗證的設備性能，包括靈敏度、特異性、檢測極限、重複性、精密度、干擾評估、檢體穩定性，以及在適當情況下與組織檢測的一致性。投資應集中於穩健的預分析系統、標準化的工作流程和自動化的檢體到結果平台，以減少變異性並支援可擴展的部署。開發人員應圍繞臨床適用的乳癌生物標記、治療抗藥性機制、分子亞型相關性以及符合腫瘤學指南和實際臨床需求的縱向監測案例來設計檢測方法。證據的產生應包括前瞻性臨床試驗、多樣化的患者群體、真實世界表現評估、健康經濟學評估以及清晰的臨床效用論證。與醫院、分子病理檢查室、生物樣本庫、學術腫瘤學網路和癌症登記處建立合作關係可以加速檢驗和部署。領導者還需要加強軟體驅動型醫療設備的監管合規性、網路安全、資料管治、人工智慧透明度、上市後效能監測和品管。為了改善醫療服務取得途徑，各機構應考慮分階段檢測模式、區域參考檢查室策略、培訓計畫、臨床醫生教育以及適用於資源豐富和新興醫療環境的工作流程。

調查方法

本執行摘要採用結構化的二級研究途徑編寫，重點關注與乳癌液態生物檢體檢測設備相關的檢驗且有數據支持的資訊來源。調查方法包括對同行評審的腫瘤學和分子診斷文獻、臨床實踐指南、監管出版刊物、公共衛生資料、癌症控制文件、體外診斷醫療設備標準、技術評估材料以及已發表的關於精準腫瘤學應用的證據進行回顧。特別強調臨床確立的生物標記分類、檢驗的檢測技術、監管考量、分析前和分析階段的品質要求，以及跨地區、跨群體和跨國家的應用因素。透過交叉引用科學證據、醫療基礎設施指標、診斷工作流程要求、與臨床指南的一致性以及精準腫瘤學的應用趨勢，整合了相關見解。本分析不包括推測性的市場規模、市場佔有率和預測。本研究結果的總結方式有助於從策略角度理解技術應用、臨床效用、區域部署準備、營運重點和證據要求，同時與實證醫學和診斷設備評估標準保持一致。

結論

乳癌液態生物檢體設備正在改變精準腫瘤學，它能夠以微創、高度可重複的方式，基於生物標記評估疾病狀態、腫瘤進展和治療抗藥性。當其被整合到檢驗的診療路徑中，並輔以高品質的檢體處理、分析能力強的平台、具有臨床指導意義的報告以及多學科解讀時，其臨床價值將得到最大程度的發揮。人工智慧、自動化、多參數檢測和協作式臨床決策系統可望進一步提升診斷效能和工作流程效率，前提是它們能夠滿足嚴格的透明度、檢驗、品管和監管合規標準。區域部署將繼續受到醫療基礎設施、保險報銷、檢查室能力、臨床醫生教育、數據管治以及獲得先進腫瘤服務的可及性的影響。專注於證據生成、操作標準化、可負擔性和全球適用性的行業相關人員最有能力支持液態生物檢體在乳癌治療中更廣泛的臨床應用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章乳癌液態生物檢體設備市場：依技術分類

  • 數位PCR
    • 晶片式數位PCR
    • 液滴式數位PCR
  • 次世代定序
    • 標靶定序
    • 全EXOME定序
    • 全基因測序
  • 即時PCR
    • 使用染料的PCR
    • 基於探針的PCR

第8章乳癌液態生物檢體設備市場：依檢測類型分類

  • 用於體外診斷
    • 裝置
    • 試劑
  • 實驗室自建檢測 (LDT)

第9章乳癌液態生物檢體設備市場：依樣本類型分類

  • 電漿
  • 血清
  • 全血

第10章：乳癌液態生物檢體設備市場：依適應症分類

  • 早期檢測
  • 預後
  • 復發檢測
  • 監測治療進展

第11章乳癌液態生物檢體設備市場：按應用領域分類

  • 循環性腫瘤細胞
  • 循環腫瘤DNA
  • 外泌體

第12章乳癌液態生物檢體設備市場：依最終用戶分類

  • 受託研究機構
  • 診斷檢查室
  • 醫院和診所
  • 研究中心

第13章乳癌液態生物檢體設備市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第14章乳癌液態生物檢體設備市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第15章乳癌液態生物檢體設備市場：按國家/地區分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Agena Bioscience, Inc.
  • ANGLE plc
  • Bio-Rad Laboratories, Inc.
  • Biocept, Inc.
  • Burning Rock Biotech Limited
  • Canexia Health Inc.
  • Cynvenio Biosystems, Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Foundation Medicine, Inc.
  • Freenome Holdings, Inc.
  • GRAIL, LLC
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Lucence Health Inc.
  • Menarini Silicon Biosystems SpA
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics, Inc.
  • OncoCyte Corporation
  • Personalis, Inc.
  • Predicine, Inc.
  • QIAGEN NV
  • SeekIn Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-742BD517C0D8

The Breast Cancer Liquid Biopsy Testing Devices Market is projected to grow by USD 2.44 billion at a CAGR of 8.41% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.38 billion
Estimated Year [2026] USD 1.49 billion
Forecast Year [2032] USD 2.44 billion
CAGR (%) 8.41%

Breast cancer liquid biopsy testing devices are becoming increasingly important in precision oncology by enabling minimally invasive detection and longitudinal monitoring of tumor-derived biomarkers in blood and other body fluids. These devices support analysis of circulating tumor DNA, circulating tumor cells, extracellular vesicles, microRNAs, methylation signatures, fragmentomic patterns, and protein-based markers, helping clinicians complement tissue biopsy when tumor access is limited, disease is heterogeneous, or repeated sampling is clinically necessary. In breast cancer care, liquid biopsy is especially relevant for identifying actionable genomic alterations, monitoring treatment response, detecting emerging resistance, and supporting therapy selection in advanced or metastatic disease. The field is being shaped by rapid progress in next-generation sequencing, digital PCR, microfluidics, automated sample preparation, high-sensitivity enrichment technologies, and bioinformatics platforms that improve analytical sensitivity and workflow reproducibility. Regulatory expectations, clinical validation requirements, data integrity standards, and reimbursement pathways remain central to adoption, as healthcare systems increasingly require evidence that liquid biopsy testing improves decision-making, patient outcomes, and resource utilization without replacing clinically necessary tissue pathology.

Transformative Shifts in the Breast Cancer Liquid Biopsy Landscape

The breast cancer liquid biopsy landscape is shifting from exploratory biomarker research toward clinically integrated diagnostic workflows. A key transformation is the move from single-marker assays to broader multi-analyte and multi-gene approaches capable of capturing tumor heterogeneity across metastatic sites and tracking resistance mechanisms such as endocrine therapy escape and targeted therapy resistance. Devices are also evolving from highly manual centralized laboratory instruments toward more automated, standardized, and potentially decentralized testing platforms that reduce turnaround time and sample handling variability. Clinical use is expanding beyond mutation detection to include measurable residual disease research, therapy resistance surveillance, molecular relapse monitoring, and real-time disease monitoring, although implementation depends on robust evidence and alignment with clinical guidelines. Another major shift is the growing emphasis on pre-analytical quality, including blood collection tube performance, plasma separation protocols, nucleic acid preservation, hemolysis assessment, leukocyte contamination control, and chain-of-custody procedures, as these factors directly influence test reliability. Interoperability with electronic health records, molecular tumor boards, laboratory information systems, and clinical decision support systems is further transforming liquid biopsy from a standalone test into a connected precision medicine tool.

Cumulative Impact of Artificial Intelligence on Liquid Biopsy Testing

Artificial intelligence is accelerating the development and clinical utility of breast cancer liquid biopsy testing devices by improving signal detection, variant interpretation, assay optimization, and workflow automation. AI-enabled bioinformatics can help distinguish low-frequency tumor-derived variants from sequencing noise, clonal hematopoiesis, germline background, and technical artifacts, which is essential for high-sensitivity applications such as recurrence monitoring and low-burden disease assessment. Machine learning models are also being used to integrate genomic, fragmentomic, epigenomic, proteomic, imaging, pathology, treatment history, and clinical data to support more comprehensive cancer profiling. In device development, AI can optimize microfluidic capture, image-based circulating tumor cell detection, digital pathology correlation, laboratory quality control, and throughput management. However, the cumulative impact of AI depends on transparent validation, representative training datasets, bias mitigation, explainability, cybersecurity, auditability, and regulatory-grade documentation. For clinical adoption, AI-driven liquid biopsy systems must demonstrate reproducibility across populations, specimen types, instruments, sequencing chemistries, and laboratory environments while maintaining clinician trust and compliance with data protection standards.

Key Regional Insights Across Asia-Pacific, Europe, North America, Latin America, Africa, and Middle East

Asia-Pacific is a high-priority region for breast cancer liquid biopsy testing devices due to rising cancer screening activity, expanding oncology infrastructure, and increasing use of molecular diagnostics in countries such as China, India, Japan, South Korea, and Australia. The region shows strong demand for scalable testing workflows that can address diverse healthcare settings, from advanced urban cancer centers to resource-constrained facilities, while public health authorities continue to emphasize earlier cancer detection and improved access to pathology services. Europe demonstrates strong momentum through guideline-driven oncology care, cross-border research collaboration, national cancer plans, and regulatory emphasis on diagnostic quality, data protection, clinical evidence, and in vitro diagnostic performance. North America remains a leading environment for clinical implementation because of mature precision oncology networks, established molecular pathology capacity, active clinical trial ecosystems, structured regulatory oversight, and broad integration of genomic profiling in advanced cancer care. In Latin America, adoption is progressing through private oncology networks, academic cancer centers, and regional efforts to improve access to advanced diagnostics, although affordability, out-of-pocket exposure, reimbursement variability, and uneven laboratory infrastructure remain important barriers. Africa presents a more uneven adoption profile, with opportunities linked to centralized reference laboratories, international research partnerships, and efforts to expand cancer diagnostic access, while constraints include infrastructure gaps, workforce shortages, late-stage diagnosis, and cost sensitivity. The Middle East is investing in oncology modernization, genomic medicine programs, tertiary care infrastructure, and national health transformation initiatives, supporting selective adoption of liquid biopsy in advanced breast cancer management where specialist oncology services and molecular laboratories are available.

Key Group Insights Across NATO, G7, BRICS, European Union, ASEAN, and GCC

NATO member countries include many advanced healthcare systems with demand for interoperable, secure, and resilient diagnostic technologies, particularly where precision oncology is embedded in national cancer control strategies and where cybersecurity, continuity of care, and protected health data exchange are high priorities. G7 countries generally support faster integration of breast cancer liquid biopsy testing devices through established clinical research networks, specialist oncology centers, mature molecular pathology infrastructure, and advanced reimbursement discussions, though evidence thresholds for clinical utility, analytical validity, and cost-effectiveness remain rigorous. BRICS economies represent a diverse opportunity base, combining large patient populations, expanding oncology infrastructure, increasing domestic interest in molecular diagnostics, and policy attention to cancer care access, but adoption is shaped by pricing pressure, regulatory differences, local manufacturing priorities, and unequal access between urban and rural settings. The European Union offers a structured environment for adoption through harmonized in vitro diagnostic regulation, strong public health systems, cross-border research programs, and emphasis on evidence-based diagnostics, while implementation varies by reimbursement policy, national molecular testing capacity, and regional laboratory networks. ASEAN countries are increasingly relevant as healthcare systems expand cancer diagnostics, regional laboratory capacity, and specialist oncology services, with adoption most visible in higher-capacity markets and private specialty care. The GCC benefits from government-backed healthcare transformation, growing genomic medicine initiatives, digital health investment, and advanced oncology service development, creating demand for high-quality liquid biopsy workflows that align with international clinical standards and accredited laboratory practice.

Key Country Insights for Breast Cancer Liquid Biopsy Testing Devices

China is rapidly expanding cancer genomics, hospital-based molecular diagnostics, clinical oncology research, and domestic device development, supporting broad interest in liquid biopsy technologies for breast cancer management. The United States is a major adopter of breast cancer liquid biopsy testing devices due to advanced oncology care pathways, broad clinical trial activity, established molecular profiling in metastatic disease, and active regulatory engagement around high-complexity diagnostics. Japan's adoption is supported by advanced healthcare infrastructure, precision medicine policy, high diagnostic quality standards, and strong integration of molecular testing into specialist oncology care. India presents strong long-term potential due to high disease burden, expanding private healthcare, growing molecular laboratory networks, and demand for cost-effective testing suited to varied care settings. Germany has strong diagnostic laboratory expertise, oncology research capacity, and regulatory rigor, while the United Kingdom supports molecular testing through national cancer strategies and centralized genomics services, creating a structured pathway for clinically validated liquid biopsy use. Australia benefits from strong cancer registries, academic research, molecular pathology expertise, and national attention to equitable access across geographically dispersed populations, while France emphasizes validated precision medicine integration through cancer networks and clinical programs. South Korea combines advanced digital health infrastructure, strong biotechnology capabilities, and high clinical interest in precision oncology, supporting adoption in tertiary hospitals and research-oriented cancer centers. Italy and Spain are advancing molecular oncology adoption through specialist hospitals and research networks, with reimbursement and regional healthcare differences influencing implementation. Canada emphasizes evidence-based integration through provincial healthcare systems and cancer agencies, with access shaped by reimbursement and laboratory capacity. Russia has expanding oncology modernization initiatives, although access, regional healthcare variation, and international technology availability can differ. Brazil leads much of Latin America in specialized oncology infrastructure, with liquid biopsy adoption concentrated in major urban centers, while Mexico is seeing growing use in private oncology and reference laboratory settings, supported by demand for less invasive diagnostics but constrained by cost variability.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated device performance, including sensitivity, specificity, limit of detection, reproducibility, precision, interference assessment, sample stability, and concordance with tissue-based testing where appropriate. Investment should focus on robust pre-analytical systems, standardized workflows, and automated sample-to-result platforms that reduce variability and support scalable implementation. Developers should design assays around clinically actionable breast cancer biomarkers, treatment resistance mechanisms, molecular subtype relevance, and longitudinal monitoring use cases that align with oncology guidelines and real-world clinical needs. Evidence generation should include prospective clinical studies, diverse patient populations, real-world performance evaluation, health economic assessment, and clear demonstration of clinical utility. Partnerships with hospitals, molecular pathology laboratories, biobanks, academic oncology networks, and cancer registries can accelerate validation and adoption. Leaders should also strengthen regulatory readiness, cybersecurity, data governance, AI transparency, post-market performance monitoring, and quality management for software-enabled devices. To improve access, organizations should consider tiered testing models, regional reference laboratory strategies, training programs, clinician education, and workflows that fit both high-resource and emerging healthcare settings.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified, data-backed sources relevant to breast cancer liquid biopsy testing devices. The methodology includes review of peer-reviewed oncology and molecular diagnostics literature, clinical practice guidelines, regulatory agency publications, public health resources, cancer control documentation, in vitro diagnostic standards, technology assessment materials, and published evidence on precision oncology implementation. Emphasis is placed on clinically established biomarker categories, validated testing technologies, regulatory considerations, pre-analytical and analytical quality requirements, and documented adoption factors across regions, groups, and countries. Insights are synthesized through triangulation across scientific evidence, healthcare infrastructure indicators, diagnostic workflow requirements, clinical guideline alignment, and precision oncology implementation trends. The analysis excludes speculative market sizing, market share, and forecasting. Findings are framed to support strategic understanding of technology adoption, clinical utility, regional readiness, operational priorities, and evidence requirements while maintaining consistency with evidence-based healthcare and diagnostic device evaluation standards.

Conclusion

Breast cancer liquid biopsy testing devices are reshaping precision oncology by enabling minimally invasive, repeatable, and biomarker-driven assessment of disease status, tumor evolution, and therapeutic resistance. Their clinical value is strongest when integrated into validated care pathways, supported by high-quality sample handling, analytically robust platforms, clinically actionable reporting, and multidisciplinary interpretation. Artificial intelligence, automation, multi-analyte testing, and connected clinical decision systems are expected to further improve diagnostic performance and workflow efficiency, provided they meet rigorous standards for transparency, validation, quality control, and regulatory compliance. Regional adoption will remain influenced by healthcare infrastructure, reimbursement, laboratory capacity, clinician education, data governance, and access to advanced oncology services. Industry participants that focus on evidence generation, operational standardization, affordability, and global adaptability will be best positioned to support broader clinical use of liquid biopsy in breast cancer care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Breast Cancer Liquid Biopsy Testing Devices Market, by Technology

  • 7.1. Introduction
  • 7.2. Digital PCR
    • 7.2.1. Chip Based Digital PCR
    • 7.2.2. Droplet Digital PCR
  • 7.3. Next Generation Sequencing
    • 7.3.1. Targeted Sequencing
    • 7.3.2. Whole Exome Sequencing
    • 7.3.3. Whole Genome Sequencing
  • 7.4. Real Time PCR
    • 7.4.1. Dye Based PCR
    • 7.4.2. Probe Based PCR

8. Breast Cancer Liquid Biopsy Testing Devices Market, by Test Type

  • 8.1. Introduction
  • 8.2. In Vitro Diagnostic
    • 8.2.1. Instruments
    • 8.2.2. Reagents
  • 8.3. Laboratory Developed Test

9. Breast Cancer Liquid Biopsy Testing Devices Market, by Sample Type

  • 9.1. Introduction
  • 9.2. Plasma
  • 9.3. Serum
  • 9.4. Whole Blood

10. Breast Cancer Liquid Biopsy Testing Devices Market, by Indication

  • 10.1. Introduction
  • 10.2. Early Detection
  • 10.3. Prognosis
  • 10.4. Recurrence Detection
  • 10.5. Treatment Monitoring

11. Breast Cancer Liquid Biopsy Testing Devices Market, by Application

  • 11.1. Introduction
  • 11.2. Circulating Tumor Cells
  • 11.3. Circulating Tumor DNA
  • 11.4. Exosomes

12. Breast Cancer Liquid Biopsy Testing Devices Market, by End User

  • 12.1. Introduction
  • 12.2. Contract Research Organizations
  • 12.3. Diagnostic Laboratories
  • 12.4. Hospitals And Clinics
  • 12.5. Research Centers

13. Breast Cancer Liquid Biopsy Testing Devices Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Africa
  • 13.6. Middle East

14. Breast Cancer Liquid Biopsy Testing Devices Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. BRICS
  • 14.4. European Union
  • 14.5. ASEAN
  • 14.6. GCC

15. Breast Cancer Liquid Biopsy Testing Devices Market, by Country

  • 15.1. China
  • 15.2. United States
  • 15.3. Japan
  • 15.4. India
  • 15.5. Germany
  • 15.6. United Kingdom
  • 15.7. Australia
  • 15.8. France
  • 15.9. South Korea
  • 15.10. Italy
  • 15.11. Canada
  • 15.12. Russia
  • 15.13. Brazil
  • 15.14. Mexico
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Agena Bioscience, Inc.
  • 17.2. ANGLE plc
  • 17.3. Bio-Rad Laboratories, Inc.
  • 17.4. Biocept, Inc.
  • 17.5. Burning Rock Biotech Limited
  • 17.6. Canexia Health Inc.
  • 17.7. Cynvenio Biosystems, Inc.
  • 17.8. Exact Sciences Corporation
  • 17.9. F. Hoffmann-La Roche Ltd
  • 17.10. Foundation Medicine, Inc.
  • 17.11. Freenome Holdings, Inc.
  • 17.12. GRAIL, LLC
  • 17.13. Guardant Health, Inc.
  • 17.14. Illumina, Inc.
  • 17.15. Lucence Health Inc.
  • 17.16. Menarini Silicon Biosystems S.p.A.
  • 17.17. Myriad Genetics, Inc.
  • 17.18. Natera, Inc.
  • 17.19. NeoGenomics, Inc.
  • 17.20. OncoCyte Corporation
  • 17.21. Personalis, Inc.
  • 17.22. Predicine, Inc.
  • 17.23. QIAGEN N.V.
  • 17.24. SeekIn Inc.
  • 17.25. Sysmex Corporation
  • 17.26. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIGITAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIGITAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIGITAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHIP BASED DIGITAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHIP BASED DIGITAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHIP BASED DIGITAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DROPLET DIGITAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DROPLET DIGITAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DROPLET DIGITAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL WHOLE EXOME SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL WHOLE EXOME SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL WHOLE EXOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL REAL TIME PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL REAL TIME PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL REAL TIME PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DYE BASED PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DYE BASED PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DYE BASED PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROBE BASED PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PROBE BASED PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROBE BASED PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IN VITRO DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IN VITRO DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IN VITRO DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LABORATORY DEVELOPED TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LABORATORY DEVELOPED TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LABORATORY DEVELOPED TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SERUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SERUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL WHOLE BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL WHOLE BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL WHOLE BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL EARLY DETECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL EARLY DETECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL EARLY DETECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PROGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PROGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RECURRENCE DETECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RECURRENCE DETECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RECURRENCE DETECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TREATMENT MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TREATMENT MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TREATMENT MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CIRCULATING TUMOR DNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CIRCULATING TUMOR DNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CIRCULATING TUMOR DNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL EXOSOMES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL EXOSOMES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL EXOSOMES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL RESEARCH CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RESEARCH CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RESEARCH CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. NATO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. NATO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. NATO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 164. NATO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 165. NATO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 166. NATO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. NATO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 168. NATO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. NATO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. NATO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. NATO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. G7 BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. G7 BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 175. G7 BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 176. G7 BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 177. G7 BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. G7 BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 179. G7 BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. G7 BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. G7 BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 219. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 220. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 221. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 223. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 225. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 253. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 254. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 255. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 257. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 264. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 265. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 266. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 268. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 270. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 271. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 274. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 275. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 276. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 277. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 279. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 281. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 282. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 296. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 297. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 298. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 299. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 301. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 303. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 304. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION